Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (278529602-SFB1243-A09, 360372040–SFB 1335-P08, 322359157-FOR2599-A03, 278529602-SFB 1243-A14, 210592381-SFB 1054-B06, 408885537-TRR 274-A01, 390857198-EXC 2145, 213904703-TRR 128-A07, 210592381-SFB 1054-A06, 369799452-SFB/TRR 237-B14, 391217598-KR2199/10-1)
Helmholtz Association (Helmholtz AI ZT-I-PF-5-01)
Received: 8 March 2021
Accepted: 24 May 2022
First Online: 16 June 2022
: F.J.T. reports receiving consulting fees from Roche Diagnostics GmbH, Immunai Inc., Singularity Bio B.V., CytoReason Ltd, and Omniscope Ltd Inc., and has an ownership interest in Cellarity, Inc. and Dermagnostix GmbH. VB is a full-time employee of Cellarity Inc. and reports ownership interest in Cellarity Inc.; the present work was carried out at Helmholtz Munich. The other authors declare no competing interests.